| 000 | 02551cam a2200217 4500500 | ||
|---|---|---|---|
| 005 | 20250518053819.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aDi Stefano, G. _eauthor |
| 700 | 1 | 0 |
_a Falco, P. _eauthor |
| 700 | 1 | 0 |
_a Galosi, E. _eauthor |
| 700 | 1 | 0 |
_a Di Pietro, G. _eauthor |
| 700 | 1 | 0 |
_a Leone, C. _eauthor |
| 700 | 1 | 0 |
_a Authier, Nicolas _eauthor |
| 245 | 0 | 0 | _aA systematic review and meta-analysis of neuropathic pain associated with COVID-19 |
| 260 | _c2024. | ||
| 500 | _a6 | ||
| 520 | _aBackground and objectiveNeuropathic pain is a complication of COVID-19 that has been occasionally reported and has received increased attention in the scientific literature. In this systematic review and meta-analysis, we aimed to provide information on the frequency of neuropathic pain associated with COVID-19.Databases and data treatmentWe systematically reviewed and analyzed literature regarding neuropathic pain associated with COVID-19. Literature searches were conducted in the PubMed, EMBASE, and Cochrane Library databases. We considered prospective and retrospective studies published up until September 2022 (limitations included English language, full-text publications, and studies including at least 10 patients). A random-effects meta-analysis was performed and heterogeneity and publication bias were assessed.ResultsWe identified 149 studies. We included 17 studies in the systematic review, and included 6 studies reporting the frequency of neuropathic pain in the acute/subacute phase of COVID-19 in the meta-analysis. The estimated frequency of neuropathic pain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95% CI: 5%–15%), with a high level of heterogeneity (Chi2 = 104; Tau2 = 0.004; df = 5; I2 = 95%; test for overall effect: Z = 3.584; p ConclusionsThe estimated frequency of neuropathic pain associated with COVID-19 should be interpreted with caution due to the high heterogeneity across studies and the lack of clear diagnostic criteria. Significance: Emerging evidence supports the development of neuropathic pain as a complication of COVID-19. However, longitudinal studies that enroll consecutive patients with COVID-19 and establish clear diagnostic criteria for neuropathic pain are needed to better assess the frequency of this condition. | ||
| 786 | 0 | _nDouleur et analgésie | 37 | 3 | 2024-12-06 | p. 181-190 | 1011-288X | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-douleur-et-analgesie-2024-3-page-181?lang=en&redirect-ssocas=7080 |
| 999 |
_c1366009 _d1366009 |
||